Janus Henderson Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-293,385
| Closed | -$12M | – | 2574 |
|
|
2024
Q2 | $12M | Buy |
293,385
+256,143
| +688% | +$10.5M | 0.01% | 652 |
|
|
2024
Q1 | $1.57M | Sell |
37,242
-18
| -0% | -$761 | ﹤0.01% | 1398 |
|
|
2023
Q4 | $1.58M | Buy |
37,260
+9,399
| +34% | +$398K | ﹤0.01% | 1366 |
|
|
2023
Q3 | $608K | Sell |
27,861
-956,134
| -97% | -$20.9M | ﹤0.01% | 1832 |
|
|
2023
Q2 | $31.3M | Sell |
983,995
-84,563
| -8% | -$2.69M | 0.02% | 487 |
|
|
2023
Q1 | $26.1M | Sell |
1,068,558
-82,763
| -7% | -$2.02M | 0.02% | 511 |
|
|
2022
Q4 | $36.3M | Sell |
1,151,321
-1,614,599
| -58% | -$50.9M | 0.03% | 442 |
|
|
2022
Q3 | $78.2M | Buy |
2,765,920
+2,752,514
| +20,532% | +$77.8M | 0.03% | 412 |
|
|
2022
Q2 | $355K | Buy |
13,406
+3,198
| +31% | +$84.7K | ﹤0.01% | 1978 |
|
|
2022
Q1 | $358K | Buy |
+10,208
| New | +$358K | ﹤0.01% | 2113 |
|